Core Insights - Eddie Pharmaceuticals' stock price increased by 2.20% on September 24, reaching 14.87 CNY per share, with a market capitalization of 6.257 billion CNY [1] - The company has seen a year-to-date stock price increase of 89.19%, but has experienced a decline of 2.11% over the last five trading days and 11.86% over the last twenty days [1] - For the first half of 2025, Eddie Pharmaceuticals reported a revenue of 362 million CNY, representing a year-on-year growth of 100.19%, and a net profit of 9.191 million CNY, up 120.23% year-on-year [2] Company Overview - Eddie Pharmaceuticals, established on December 15, 2009, and listed on July 20, 2020, is based in Yangzhou, Jiangsu Province [1] - The company's main business involves the exploration, research, and sales of innovative chemical drugs and human-derived protein products, with revenue composition as follows: human-derived protein 41.11%, new drugs 35.69%, diagnostic equipment and reagents 13.62%, generic drugs 9.47%, and others 0.11% [1] - As of June 30, 2025, the number of shareholders increased by 34.45% to 11,900, while the average circulating shares per person decreased by 25.62% to 35,247 shares [2] Financial Performance - Since its A-share listing, Eddie Pharmaceuticals has distributed a total of 20.16 million CNY in dividends, with no dividends paid in the last three years [3] - As of June 30, 2025, the top ten circulating shareholders include Penghua Medical Technology Stock A and new entrants such as招商行业精选股票 and 广发价值核心混合A, indicating a shift in institutional holdings [3]

Group 1 - The core point of the news is that Aidi Pharmaceutical's stock price dropped by 5.03% to 14.74 CNY per share, with a total market capitalization of 6.202 billion CNY as of the report date [1] - Aidi Pharmaceutical, established on December 15, 2009, and listed on July 20, 2020, is based in Yangzhou, Jiangsu Province, and focuses on the exploration, research, and sales of innovative chemical drugs and human-derived protein products [1] - The company's revenue composition includes human-derived proteins at 41.11%, new drugs at 35.69%, diagnostic equipment, reagents, and others at 13.62%, generic drugs at 9.47%, and other supplementary products at 0.11% [1] Group 2 - Among Aidi Pharmaceutical's top ten circulating shareholders, one fund from GF Fund Management, the GF Value Core Mixed A (010377), entered the top ten in the second quarter, holding 3.931 million shares, which is 0.93% of the circulating shares [2] - The GF Value Core Mixed A fund, established on January 22, 2021, has a latest scale of 3.516 billion CNY, with a year-to-date return of 62.56% and a one-year return of 110.84% [2] - The fund manager, Wu Yuanyi, has been in position for nearly 4 years, with the fund's total asset scale at 20.478 billion CNY and a best return of 112.4% during his tenure [3]

Group 1 - The core viewpoint of the news is that Eddy Pharmaceutical has seen a 5% increase in stock price, reaching 15.95 CNY per share, with a total market capitalization of 6.711 billion CNY [1] - Eddy Pharmaceutical, established on December 15, 2009, and listed on July 20, 2020, focuses on the exploration, research, and sales of innovative chemical drugs and human-derived protein products [1] - The revenue composition of Eddy Pharmaceutical includes human-derived proteins at 41.11%, new drugs at 35.69%, diagnostic equipment and reagents at 13.62%, generic drugs at 9.47%, and other supplementary products at 0.11% [1] Group 2 - According to data, the Guotou Ruijin Fund has a significant holding in Eddy Pharmaceutical, with the Guotou Ruijin Specialized and New Quantitative Stock Selection Mixed A Fund (015842) holding 76,300 shares, accounting for 1.39% of the fund's net value [2] - The Guotou Ruijin Specialized and New Quantitative Stock Selection Mixed A Fund has achieved a year-to-date return of 51.3% and a one-year return of 113.06%, ranking 894 out of 8172 and 352 out of 7980 in its category, respectively [2] - The fund manager, Zhao Jian, has been in position for nearly 12 years, with the fund's total asset size at 3.848 billion CNY and a best return of 172.91% during his tenure [3]